Preview

Онкоурология

Расширенный поиск

Эффективность применения вакцины Онкофаг у больных раком почки

https://doi.org/10.17650/1726-9776-2008-4-4-17-21

Полный текст:

Об авторах

О. Б. Карякин
ГУ МРНЦ РАМН
Россия
Обнинск


А. М. Попов
ГУ МРНЦ РАМН
Россия
Обнинск


Список литературы

1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2005 году (заболеваемость и смертность). М., 2007.

2. Tsui K.H., Shvarts O., Smith R.B. et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 1090—5.

3. Pizzocaro G., Piva L., Colavita M. et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19:425—31.

4. Giuliani L., Giberti C., Martorana G., Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990;143: 468—73.

5. Messing E.M., Manola J., Wilding G. et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214—22.

6. Negrier S., Perol D. et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal cell carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110(11):2468—77.

7. Kim H.L., Seligson D., Liu X. et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10(16):5464—71.

8. Kunkle D.A., Crispen P.L., Li T., Uzzo R.G. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol 2007;177:1692—6.

9. Zisman A., Pantuck A.J., Wieder J. et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559—66.

10. Shvarts O., Lam J.S., Kim H.L., Belldegrun A.S. Staging of renal cell carcinoma: current concepts. BJU Int 2005;95(suppl 2):8—13.

11. Frank I., Blute M.L., Cheville J.C. et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003;170:2225—32.

12. Zisman A., Pantuck A.J., Dorey F. et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649—57.

13. Kattan M.W., Reuter V., Motzer R.J. et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63—7.

14. Galfano A., Novara G., Iafrate M. et al. Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 2008;80(2):113—23.

15. Fyfe G., Fisher R.I., Rosenberg S.A. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688—96.

16. MRCRC Collaborators. Interferonalpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14—7.

17. McDermott D.F., Regan M.M., Clark J.I. et al. Randomized phase III trial of high-dose interleukin-2 vs subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133—41.

18. Pyrhonen S., Salminen E., Ruutu M. et al. Prospective randomized trial of interferon alfa-2a plus vinblastine vs vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859—67.

19. Yang J.C., Sherry R.M., Steinberg S.M. et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127—32.

20. Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125—34.

21. Motzer R.J., Hutson T.E., Pharm D. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115—24.

22. Haas N. Update on targeted therapy adjuvant trials (ECOG/MRC). 5th International Symposium of the Kidney Cancer Association. Chicago, IL, USA; Sept 22-23, 2006.

23. Jocham D., Richter A., Homann L. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594—9.

24. Doehn C., Richter A., Theodor R. et al. Prolongation of progression-free and overall survival following an adjuvant vaccination with Reniale in patients with nonmetastatic renal cell carcinoma: secondary analysis of a multicenter phase-III trial. Onkologie 2006;29(3 suppl):58.

25. Holtl L., Zelle-Rieser C., Gander H. et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002;8:3369—76.

26. Galligioni E., Quaia M., Merlo A. et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: Five-year results of a prospective randomized study. Cancer 1996;77:2560—6.

27. Wood C., Srivastava P., Bukowski R. et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008;372(9633):145—54.

28. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002;20:395—425.

29. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995;269:1585—8.

30. Jonasch E., Wood C., Tamboli P. et al. Vaccination of renal cell carcinoma patients with autologous tumor-derived vitespen vaccine: clinical findings. Br J Cancer 2008;98(8):1336—41.

31. Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17: 2530—40.

32. Joint Committee on Cancer. Kidney cancer. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC cancer staging manual, 6th edn. New York: Springer, 2002: 323—25.


Для цитирования:


Карякин О.Б., Попов А.М. Эффективность применения вакцины Онкофаг у больных раком почки. Онкоурология. 2008;4(4):17-20. https://doi.org/10.17650/1726-9776-2008-4-4-17-21

For citation:


Karyakin O.B., Popov A.M. Efficacy of vaccine Oncophage application in patients with renal cancer. Cancer Urology. 2008;4(4):17-20. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-4-17-21

Просмотров: 7


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X